Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.
Human immunodeficiency virus type 2 (HIV-2)-infected individuals develop immunodeficiency with a considerable delay and transmit the virus at rates lower than HIV-1-infected persons. Conceivably, comparative studies on the immune responsiveness of HIV-1- and HIV-2-infected hosts may help to explain the differences in pathogenesis and transmission between the two types of infection. Previous studies have shown that the neutralizing antibody response is more potent and broader in HIV-2 than in HIV-1 infection. In the present study, we have examined further the function of the humoral immune response and studied the effect of complement on the antiviral activity of plasma from singly HIV-1- or HIV-2-infected individuals, as well as HIV-1/HIV-2 dually infected individuals. The neutralization and antibody-dependent complement-mediated inactivation of HIV-1 and HIV-2 isolates were tested in a plaque reduction assay using U87.CD4.CCR5 cells. The results showed that the addition of complement increased intratype antiviral activities of both HIV-1 and HIV-2 plasma samples, although the complement effect was more pronounced with HIV-2 than HIV-1 plasma. Using an area-under-the-curve (AUC)-based readout, multivariate statistical analysis confirmed that the type of HIV infection was independently associated with the magnitude of the complement effect. The analyses carried out with purified IgG indicated that the complement effect was largely exerted through the classical complement pathway involving IgG in both HIV-1 and HIV-2 infections. In summary, these findings suggest that antibody binding to HIV-2 structures facilitates the efficient use of complement and thereby may be one factor contributing to a strong antiviral activity present in HIV-2 infection.
Department of Laboratory Medicine, Lund University, Lund, Sweden.
Gülşen
G
Özkaya Şahin
Birgitta
B
Holmgren
Enas
E
Sheik-Khalil
Zacarias
Z
da Silva
Jens
J
Nielsen
Salma
S
Nowroozalizadeh
Fredrik
F
Månsson
Hans
H
Norrgren
Peter
P
Aaby
Eva Maria
EM
Fenyö
Marianne
M
Jansson
D000328:Adult; D000368:Aged; D057134:Antibodies, Neutralizing / Q000097:blood; D002460:Cell Line; D003165:Complement System Proteins / Q000276:immunology*; D005260:Female; D015483:HIV Antibodies / Q000097:blood; D015497:HIV-1 / Q000276:immunology*; D015498:HIV-2 / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D010949:Plasma / Q000276:immunology* / Q000821:virology*; D010948:Viral Plaque Assay
D057134:Antibodies, Neutralizing; D015483:HIV Antibodies; D007074:Immunoglobulin G; D003165:Complement System Proteins